Merck & Co’s (NYSE: MRK) Lagevrio (molnupiravir) has been granted emergency approval by China’s National Medical Products Administration.
The oral antiviral drug will be the latest treatment to help China cope with the current outbreak of COVID-19 in the Asian country, and will be distributed by Chinese state-owned company Sinopharm, which struck a deal with Merck last year.
China is seeing cases of the virus surge after abandoning its ‘zero COVID’ strategy in December. Other medicines - including the antiviral treatment Paxlovid (nirmatrelvir/ritonavir) from another US company, Pfizer - have been in short supply amid the outbreak.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze